Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.

Patorno E, Schneeweiss S, Wang SV.

Diabetes Obes Metab. 2020 Apr;22 Suppl 3:45-59. doi: 10.1111/dom.13918. Review.

PMID:
32250527
2.

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.

Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E.

Diabetes Care. 2020 Apr;43(4):921-924. doi: 10.2337/dc19-1943. Epub 2020 Feb 10.

PMID:
32041899
3.

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

Morieri ML, Shah HS, Sjaarda J, Lenzini PA, Campbell H, Motsinger-Reif AA, Gao H, Lovato L, Prudente S, Pandolfi A, Pezzolesi MG, Sigal RJ, Paré G, Marcovina SM, Rotroff DM, Patorno E, Mercuri L, Trischitta V, Chew EY, Kraft P, Buse JB, Wagner MJ, Cresci S, Gerstein HC, Ginsberg HN, Mychaleckyj JC, Doria A.

Diabetes. 2020 Apr;69(4):771-783. doi: 10.2337/db19-0973. Epub 2020 Jan 23.

PMID:
31974142
4.

Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Fralick M, Chen SK, Patorno E, Kim SC.

Ann Intern Med. 2020 Jan 14. doi: 10.7326/M19-2610. [Epub ahead of print]

PMID:
31931526
5.

The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.

Patorno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz AJ, Bessette LG, Kulldorff M, Schneeweiss S.

Endocrinol Diabetes Metab. 2019 Nov 26;3(1):e00103. doi: 10.1002/edm2.103. eCollection 2020 Jan.

6.

Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.

Dave CV, Schneeweiss S, Kim D, Fralick M, Patorno E.

Ann Intern Med. 2019 Dec 17;171(12):944-945. doi: 10.7326/L19-0671. No abstract available.

PMID:
31842209
7.

Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.

Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L.

Lancet Diabetes Endocrinol. 2020 Jan;8(1):13-14. doi: 10.1016/S2213-8587(19)30382-1. Epub 2019 Dec 2. No abstract available.

PMID:
31806579
8.

Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the United States Medicare Data.

Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ.

J Gerontol A Biol Sci Med Sci. 2019 Sep 30. pii: glz224. doi: 10.1093/gerona/glz224. [Epub ahead of print]

PMID:
31566201
9.

Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy.

Sultana J, Fontana A, Giorgianni F, Tillati S, Cricelli C, Pasqua A, Patorno E, Ballard C, Sturkenboom M, Trifirò G.

Drug Saf. 2019 Dec;42(12):1471-1485. doi: 10.1007/s40264-019-00860-z.

PMID:
31556019
10.

Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men.

Dave CV, Schneeweiss S, Patorno E.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.2813. [Epub ahead of print] No abstract available.

PMID:
31479145
11.

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E.

Ann Intern Med. 2019 Jul 30. doi: 10.7326/M18-3136. [Epub ahead of print]

PMID:
31357213
12.

Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions.

Dave CV, Patorno E, Franklin JM, Huybrechts K, Sarpatwari A, Kesselheim AS, Bateman BT.

J Gen Intern Med. 2019 Nov;34(11):2339-2341. doi: 10.1007/s11606-019-05150-z. No abstract available.

PMID:
31309407
13.

Fracture Risk After Initiation of Use of Canagliflozin.

Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E.

Ann Intern Med. 2019 Jul 2;171(1):80. doi: 10.7326/L19-0320. No abstract available.

PMID:
31261403
14.

Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.

Patorno E, Schneeweiss S, Gopalakrishnan C, Martin D, Franklin JM.

Diabetes Care. 2019 Dec;42(12):2204-2210. doi: 10.2337/dc19-0069. Epub 2019 Jun 25.

PMID:
31239281
15.

Anticonvulsant Mood Stabilizer and Lithium Use and Risk of Adverse Pregnancy Outcomes.

Cohen JM, Huybrechts KF, Patorno E, Desai RJ, Mogun H, Bateman BT, Hernández-Díaz S.

J Clin Psychiatry. 2019 Jun 18;80(4). pii: 18m12572. doi: 10.4088/JCP.18m12572.

PMID:
31237992
16.

A tool for empirical equipoise assessment in multigroup comparative effectiveness research.

Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Hernández-Díaz S, Glynn RJ.

Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):934-941. doi: 10.1002/pds.4767. Epub 2019 May 27.

17.

Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.

Bykov K, He M, Franklin JM, Garry EM, Seeger JD, Patorno E.

Diabetes Obes Metab. 2019 Sep;21(9):2029-2038. doi: 10.1111/dom.13766. Epub 2019 May 29. Review.

18.

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.

Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

PMID:
30955357
19.

Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Patorno E, Gopalakrishnan C, Brodovicz KG, Meyers A, Bartels DB, Liu J, Kulldorff M, Schneeweiss S.

Diabetes Obes Metab. 2019 Aug;21(8):1824-1836. doi: 10.1111/dom.13735. Epub 2019 May 1.

PMID:
30941884
20.

Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries.

Sultana J, Hurtado I, Bejarano-Quisoboni D, Giorgianni F, Huybrechts KF, Lu Z, Patorno E, Sanfélix-Gimeno G, Tari DU, Trifirò G.

Eur J Clin Pharmacol. 2019 Jul;75(7):1005-1015. doi: 10.1007/s00228-019-02654-9. Epub 2019 Mar 1.

PMID:
30824947
21.

Days' Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting - United States, 2014.

Mundkur ML, Franklin JM, Abdia Y, Huybrechts KF, Patorno E, Gagne JJ, Meyer TE, Staffa J, Bateman BT.

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):140-143. doi: 10.15585/mmwr.mm6806a3.

22.

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.

Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E.

Ann Intern Med. 2019 Feb 5;170(3):155-163. doi: 10.7326/M18-0567. Epub 2019 Jan 1.

23.

Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure.

Desai RJ, Lin KJ, Patorno E, Barberio J, Lee M, Levin R, Evers T, Wang SV, Schneeweiss S.

Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004700. doi: 10.1161/CIRCOUTCOMES.118.004700.

PMID:
30562067
24.

Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.

Huybrechts KF, Hernández-Díaz S, Straub L, Gray KJ, Zhu Y, Patorno E, Desai RJ, Mogun H, Bateman BT.

JAMA. 2018 Dec 18;320(23):2429-2437. doi: 10.1001/jama.2018.18307.

25.

Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study.

Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Franklin JM, Stürmer T, Hernández-Díaz S, Glynn RJ.

Am J Epidemiol. 2019 Mar 1;188(3):609-616. doi: 10.1093/aje/kwy263.

26.

Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.

Spoendlin J, Gagne JJ, Lewey JJ, Patorno E, Schneeweiss S, Desai RJ.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1361-1370. doi: 10.1002/pds.4668. Epub 2018 Oct 31.

PMID:
30379372
27.

Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.

Dave CV, Schneeweiss S, Patorno E.

Diabetes Obes Metab. 2019 Feb;21(2):434-438. doi: 10.1111/dom.13531. Epub 2018 Oct 11.

28.

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation: Results and Challenges From the Real World.

Fralick M, Patorno E, Fischer MA.

JAMA Intern Med. 2018 Sep 1;178(9):1199-1200. doi: 10.1001/jamainternmed.2018.3025. No abstract available.

PMID:
30105365
29.

Opioid Overdose After Surgical Discharge.

Ladha KS, Gagne JJ, Patorno E, Huybrechts KF, Rathmell JP, Wang SV, Bateman BT.

JAMA. 2018 Aug 7;320(5):502-504. doi: 10.1001/jama.2018.6933. No abstract available.

30.

Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic.

Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, Nguyen M, Gagne JJ, Patorno E, Huybrechts KF, Major JM, Zhou E, Reidy M, Cosgrove A, Schneeweiss S, Kulldorff M.

Epidemiology. 2018 Nov;29(6):895-903. doi: 10.1097/EDE.0000000000000907.

31.

Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006-2015.

Mundkur ML, Franklin J, Huybrechts KF, Fischer MA, Kesselheim AS, Linder JA, Landon J, Patorno E.

Drug Saf. 2018 Dec;41(12):1333-1342. doi: 10.1007/s40264-018-0697-4.

PMID:
29987757
32.

Anticonvulsants and the risk of perinatal bleeding complications: A pregnancy cohort study.

Panchaud A, Cohen JM, Patorno E, Huybrechts KF, Desai RJ, Gray KJ, Mogun H, Hernandez-Diaz S, Bateman BT.

Neurology. 2018 Aug 7;91(6):e533-e542. doi: 10.1212/WNL.0000000000005944. Epub 2018 Jul 6.

33.

Diagnosis-based cohort augmentation using laboratory results data: The case of chronic kidney disease.

Smith DH, Shetterly S, Flory J, Haynes K, Lu CY, Gagne JJ, Herrinton L, Nyirenda C, Patorno E, Shoaibi A, Raebel MA.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):872-877. doi: 10.1002/pds.4583. Epub 2018 Jun 22.

PMID:
29932281
34.

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG).

Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, Lund JL, Patorno E, Slaughter JL, Wen X, Bennett D; ISPE Comparative Effectiveness Research Special Interest Group.

Clin Pharmacol Ther. 2018 Aug;104(2):239-241. doi: 10.1002/cpt.1086. Epub 2018 May 7.

PMID:
29733448
35.

Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.

Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF.

Am J Psychiatry. 2018 Jun 1;175(6):564-574. doi: 10.1176/appi.ajp.2018.17040393. Epub 2018 May 7.

36.

Using prescription claims to detect aberrant behaviors with opioids: comparison and validation of 5 algorithms.

Rough K, Huybrechts KF, Hernandez-Diaz S, Desai RJ, Patorno E, Bateman BT.

Pharmacoepidemiol Drug Saf. 2019 Jan;28(1):62-69. doi: 10.1002/pds.4443. Epub 2018 Apr 24.

37.

Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.

Park Y, Bateman BT, Kim DH, Hernandez-Diaz S, Patorno E, Glynn RJ, Mogun H, Huybrechts KF.

BMJ. 2018 Mar 28;360:k1218. doi: 10.1136/bmj.k1218.

38.

Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near-Real-Time Monitoring Program in Italy.

Mayer F, Kirchmayer U, Coletta P, Agabiti N, Belleudi V, Cappai G, Di Martino M, Schneeweiss S, Davoli M, Patorno E.

J Am Heart Assoc. 2018 Mar 10;7(6). pii: e008034. doi: 10.1161/JAHA.117.008034.

39.

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.

Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC.

BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119.

40.

Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study.

Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC.

J Am Heart Assoc. 2018 Jan 24;7(3). pii: e007393. doi: 10.1161/JAHA.117.007393.

41.

Can information on functional and cognitive status improve short-term mortality risk prediction among community-dwelling older people? A cohort study using a UK primary care database.

Sultana J, Fontana A, Giorgianni F, Basile G, Patorno E, Pilotto A, Molokhia M, Stewart R, Sturkenboom M, Trifirò G.

Clin Epidemiol. 2017 Dec 19;10:31-39. doi: 10.2147/CLEP.S145530. eCollection 2018.

42.

Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.

Hernandez-Diaz S, Huybrechts KF, Desai RJ, Cohen JM, Mogun H, Pennell PB, Bateman BT, Patorno E.

Neurology. 2018 Jan 23;90(4):e342-e351. doi: 10.1212/WNL.0000000000004857. Epub 2017 Dec 27.

43.

Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.

Patorno E, Gopalakrishnan C, Franklin JM, Brodovicz KG, Masso-Gonzalez E, Bartels DB, Liu J, Schneeweiss S.

Diabetes Obes Metab. 2018 Apr;20(4):974-984. doi: 10.1111/dom.13184. Epub 2018 Jan 12.

44.

Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors.

Patorno E, Gopalakrishnan C, Bartels DB, Brodovicz KG, Liu J, Schneeweiss S.

Endocrinol Diabetes Metab. 2017 Nov 27;1(1):e00005. doi: 10.1002/edm2.5. eCollection 2018 Jan.

45.

Placental Complications Associated With Psychostimulant Use in Pregnancy.

Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF.

Obstet Gynecol. 2017 Dec;130(6):1192-1201. doi: 10.1097/AOG.0000000000002362.

46.

Patterns of opioid initiation at first visits for pain in United States primary care settings.

Mundkur ML, Rough K, Huybrechts KF, Levin R, Gagne JJ, Desai RJ, Patorno E, Choudhry NK, Bateman BT.

Pharmacoepidemiol Drug Saf. 2018 May;27(5):495-503. doi: 10.1002/pds.4322. Epub 2017 Oct 2.

47.

Lithium Use in Pregnancy and the Risk of Cardiac Malformations.

Patorno E, Huybrechts KF, Hernandez-Diaz S.

N Engl J Med. 2017 Aug 31;377(9):893-894. doi: 10.1056/NEJMc1708919. No abstract available.

PMID:
28854098
48.

Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study.

Huybrechts KF, Bateman BT, Desai RJ, Hernandez-Diaz S, Rough K, Mogun H, Kerzner LS, Davis JM, Stover M, Bartels D, Cottral J, Patorno E.

BMJ. 2017 Aug 2;358:j3326. doi: 10.1136/bmj.j3326.

49.

Benzodiazepines and risk of all cause mortality in adults: cohort study.

Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF.

BMJ. 2017 Jul 6;358:j2941. doi: 10.1136/bmj.j2941.

50.

Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States.

Park Y, Huybrechts KF, Cohen JM, Bateman BT, Desai RJ, Patorno E, Mogun H, Cohen LS, Hernandez-Diaz S.

Psychiatr Serv. 2017 Nov 1;68(11):1112-1119. doi: 10.1176/appi.ps.201600408. Epub 2017 Jun 15.

Supplemental Content

Loading ...
Support Center